HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Temitayo Ajayi Selected Research

Epilepsy (Aura)

1/2021Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration.
1/2018Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Temitayo Ajayi Research Topics

Disease

5Acute Lung Injury
05/2009 - 08/2003
4Pneumonia (Pneumonitis)
05/2009 - 02/2004
3Neuronal Ceroid-Lipofuscinoses (Neuronal Ceroid Lipofuscinosis)
12/2019 - 01/2018
2Epilepsy (Aura)
01/2021 - 01/2018
2Hypersensitivity (Allergy)
01/2021 - 12/2018
2Head and Neck Neoplasms (Head and Neck Cancer)
01/2020 - 01/2019
2Infections
01/2018 - 06/2010
2Cystic Fibrosis (Mucoviscidosis)
07/2014 - 11/2010
1Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria)
01/2021
1Hemolysis
01/2021
1Fever (Fevers)
01/2021
1Chronic Disease (Chronic Diseases)
01/2021
1Rare Diseases (Rare Disease)
01/2021
1Neurodegenerative Diseases (Neurodegenerative Disease)
01/2021
1Diarrhea
01/2021
1Fatigue
01/2021
1Injection Site Reaction
01/2021
1Headache (Headaches)
01/2021
1Disease Progression
12/2019
1Dementia (Dementias)
01/2018
1Acute Kidney Injury (Acute Renal Failure)
07/2014
1Inborn Genetic Diseases (Disease, Hereditary)
07/2014
1Pulmonary Edema
05/2009
1Sepsis (Septicemia)
02/2004

Drug/Important Bio-Agent (IBA)

4Tripeptidyl-Peptidase 1IBA
01/2021 - 01/2018
3EnzymesIBA
01/2021 - 01/2018
3Proteins (Proteins, Gene)FDA Link
07/2014 - 06/2010
3Type III Secretion SystemsIBA
06/2010 - 04/2004
2cerliponase alfaIBA
01/2021 - 01/2018
2Biomarkers (Surrogate Marker)IBA
12/2019 - 05/2009
2Nonsense Codon (Nonsense Mutation)IBA
07/2014 - 11/2010
2atalurenIBA
07/2014 - 11/2010
1Peptides (Polypeptides)IBA
01/2021
1AntibodiesIBA
01/2021
1eculizumabFDA Link
01/2021
1Complement System Proteins (Complement)IBA
01/2021
1pegcetacoplanIBA
01/2021
1Hemoglobins (Hemoglobin)IBA
01/2021
1Immunoglobulin E (IgE)IBA
12/2018
1Pharmaceutical PreparationsIBA
12/2018
1Anti-Bacterial Agents (Antibiotics)IBA
01/2018
1CreatinineIBA
07/2014
1ChloridesIBA
07/2014
1Tobramycin (Nebcin)FDA LinkGeneric
07/2014
1Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA
11/2010
1Messenger RNA (mRNA)IBA
11/2010
1Cytotoxins (Cytolysins)IBA
06/2010
1Plasminogen Activators (Plasminogen Activator)IBA
05/2009
1Plasminogen Activator Inhibitor 1IBA
05/2009
1Phospholipases (Phospholipase)IBA
11/2004
1Toll-Like Receptor 4IBA
02/2004
1LipopolysaccharidesIBA
02/2004
1Immunoglobulin Fab FragmentsIBA
08/2003

Therapy/Procedure

3Therapeutics
01/2021 - 08/2003
2Radiotherapy
01/2020 - 01/2019
1Enzyme Replacement Therapy
01/2018
1Mechanical Ventilators (Ventilator)
05/2009